A controversial ruling by the US Court of Appeals for the Federal Circuit over generic labeling carve-outs should be reheard “en banc” by the full court, to correct a misinterpretation of the rules around so-called skinny labels, the Association for Accessible Medicines has urged in an amicus brief.
The case involving GlaxoSmithKline and Teva over Coreg (carvedilol) made waves earlier this year when a split appeals court decision reversed a lower court ruling on induced infringement, reinstating a finding of infringement and a $235m jury damages award from 2017 against the Israeli firm